An interventional study of heat probe or hemoclip and heat probe or hemoclip in Peptic Ulcer Bleeding, sponsored by Changhua Christian Hospital. Withdrawn at 1 site in Taiwan. Open to participants aged 18 Years to 89 Years. Per ClinicalTrials.gov, last updated 2020-05-29.
Sponsored by Changhua Christian Hospital · Not applicable, Interventional, and Treatment
The investigators used two different doses of esomeprazole (40 mg IV q.d. and 40 mg IV q6h for three days followed by esomeprazole 40 mg q.d. orally in two groups) after successful endoscopic therapy with heat probe therapy or hemoclip placement.
The goal of this study is to assess the outcomes of two different regimens of low vs. high dose of intravenous esomeprazole after endoscopic therapy in patients with peptic ulcer bleeding.
A bleeding peptic ulcer remains a serious medical problem with significant morbidity and mortality. Endoscopic therapy significantly reduces further bleeding, surgery, and mortality in patients receiving intravenous Proton Pump Inhibitor (PPI）and is now recommended as the first hemostatic modality for these patients. In the past few years, adjuvant use of a high-dose proton pump inhibitor (PPI) after endoscopic therapy has been endorsed in some studies, including two consensus statements and two meta-analysis. To sustain a high intragastric pH, a high dose of omeprazole has been used in previous studies concerning high-risk peptic ulcer bleeding. However, in one recent published metaanalysis found that low dose PPI may be as effective as high dose PPI in preventing further bleeding in high-risk patients. Therefore, one double blind study is needed clarify this puzzle.
We used two different doses of esomeprazole (40 mg IV q.d. and 40 mg IV q6h for three days followed by esomeprazole 40 mg q.d. orally in two groups) after successful endoscopic therapy with heat probe therapy or hemoclip placement.
The goal of this study is to assess the outcomes of two different regimens of low vs. high dose of intravenous esomeprazole after endoscopic therapy in patients with peptic ulcer bleeding.
193 studies on the registry are indexed under Peptic Ulcer; 31 are open to participants now.
Browse Peptic Ulcer studies →Changhua Christian Hospital is the lead sponsor of 74 studies on the registry; 10 are open to participants now.
Counted across the registry records on this site, refreshed daily.
Exclusion Criteria:
40 mg esomeprazole IV for three days followed by esomeprazole 40 mg po daily for two months
Device: heat probe or hemoclip
40 mg esomeprazole IV every 6 hr for 3 days followed by 40 mg po daily for two months
Device: heat probe or hemoclip
for hemostasis
Also known as: Olympus co.
for hemostasis
Also known as: Olympus co.
further bleeding
Number of participants with rebleeding within 14 days
Time frame: 14 days
hospital stay
hospital stay in day
Time frame: 30 days
need of blood transfusion
number of participants need of blood transufion
Time frame: 30 days
surgical intervention
number of participants need surgical intervention to manage bleeding
Time frame: 30 days
mortality
number of participants death
Time frame: 30 days
This study is withdrawn, as verified in May 2020. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Changhua Christian Hospital